QR01019 potassium

QR01019 potassium is a small molecule antihypertensive agent developed by Wuhan Langlai Pharmaceutical. It is a potassium salt formulation of a novel derivative, likely belonging to the angiotensin II receptor blocker (ARB) class, intended for the treatment of primary hypertension. The drug has been evaluated in a Phase 1 clinical trial (CTR20181075) in China to assess its safety, tolerability, and pharmacokinetics in healthy volunteers, including the impact of food on its absorption profile. As an ARB, its mechanism of action involves the selective antagonism of the angiotensin II receptor type 1 (AT1), which prevents the vasoconstrictive effects of angiotensin II, thereby lowering blood pressure.